Shield Therapeutics Banner Image

Shield Therapeutics

  • Ticker STX
    Exchange LSE More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
Shield Therapeutics Logo Image
  • 11-50 Employees
  • Based in Gateshead, England
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novelMore therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics

Most Recent Annual Report

Shield Therapeutics
MOST RECENT 2021 Annual Report

Older/Archived Annual Reports